Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events
Status: Enrolling
Updated:  2/8/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events
Status: Enrolling
Updated: 2/8/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events
Status: Enrolling
Updated:  2/8/2017
Overlake Hospital Medical Center
mi
from
Bellevue, WA
Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery
An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events
Status: Enrolling
Updated: 2/8/2017
Overlake Hospital Medical Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery
Optimal Pain Management After Video-Assisted Thoracic Surgery
Status: Enrolling
Updated:  2/8/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery
Optimal Pain Management After Video-Assisted Thoracic Surgery
Status: Enrolling
Updated: 2/8/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Tustin, CA
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Tustin, CA
Click here to add this to my saved trials
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Wichita, KA
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
McAllen, TX
Managing Wounds With Allevyn Life in a Home Health Care Environment
A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
IR and Microvascular Blood Flow in SCI
Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury
Status: Enrolling
Updated:  3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
IR and Microvascular Blood Flow in SCI
Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury
Status: Enrolling
Updated: 3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI
Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI
Status: Enrolling
Updated:  3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI
Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI
Status: Enrolling
Updated: 3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI
A Novel Application of Iontophoresis in the Transcutaneous Delivery of a Prokinetic Agent for the Promotion of Bowel Evacuation
Status: Enrolling
Updated:  3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI
A Novel Application of Iontophoresis in the Transcutaneous Delivery of a Prokinetic Agent for the Promotion of Bowel Evacuation
Status: Enrolling
Updated: 3/6/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
UCLA; Kidney & Pancreas Transplantation
mi
from
Los Angeles, CA
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
UCLA; Kidney & Pancreas Transplantation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
California Inst. of Renal Research
mi
from
San Diego, CA
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
California Inst. of Renal Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Univ of CA San Francisco; Kidney Transplant Service
mi
from
San Francisco, CA
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Univ of CA San Francisco; Kidney Transplant Service
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
University of Colorado Health Sciences Center; Dept of Medicine
mi
from
Denver, CO
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
University of Colorado Health Sciences Center; Dept of Medicine
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Georgetown Uni Hospital; Division of Transplant Surgery
mi
from
Washington,
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Georgetown Uni Hospital; Division of Transplant Surgery
mi
from
Washington,
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
MedStar Washington Hospital Center
mi
from
Washington,
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Emory University
mi
from
Atlanta, GA
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Augusta University
mi
from
Augusta, GA
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Henry Ford Health System; Gastroenterology
mi
from
Detroit, MI
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Henry Ford Health System; Gastroenterology
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Washington Uni School of Medicine/Barnes Jewish Hospital; Renal
mi
from
St Louis, MO
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Washington Uni School of Medicine/Barnes Jewish Hospital; Renal
mi
from
St Louis, MO
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Erie County Medical Center; Dept. of Nephrology
mi
from
Buffalo, NY
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Erie County Medical Center; Dept. of Nephrology
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Columbia University
mi
from
New York, NY
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
University of Cincinnati / University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
University of Cincinnati / University of Cincinnati College of Medicine
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Baylor University Medical Center
mi
from
Dallas, TX
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated:  3/7/2017
Clin Univ de Bxl Hôpital Erasme
mi
from
Bruxelles,
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients
Status: Enrolling
Updated: 3/7/2017
Clin Univ de Bxl Hôpital Erasme
mi
from
Bruxelles,
Click here to add this to my saved trials
Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury
Cardiovascular, Cerebrovascular, and Cognitive Function in SCI
Status: Enrolling
Updated:  3/9/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury
Cardiovascular, Cerebrovascular, and Cognitive Function in SCI
Status: Enrolling
Updated: 3/9/2017
James J Peters VA Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Placental Transfusion Project for Preterm Infants
Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of "Delayed" Cord Clamping and Umbilical Cord Milking
Status: Enrolling
Updated:  3/15/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Placental Transfusion Project for Preterm Infants
Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of "Delayed" Cord Clamping and Umbilical Cord Milking
Status: Enrolling
Updated: 3/15/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated:  3/16/2017
UMass Clinton Hospital
mi
from
Clinton, MA
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated: 3/16/2017
UMass Clinton Hospital
mi
from
Clinton, MA
Click here to add this to my saved trials
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated:  3/16/2017
UMass Memorial Marlborough Hospital
mi
from
Marlborough, MA
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated: 3/16/2017
UMass Memorial Marlborough Hospital
mi
from
Marlborough, MA
Click here to add this to my saved trials
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated:  3/16/2017
UMASS Memorial Medical Center
mi
from
Worcester, MA
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department
Status: Enrolling
Updated: 3/16/2017
UMASS Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Pharmacological Intervention in Depression After Traumatic Brain Injury
Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)
Status: Enrolling
Updated:  3/16/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Pharmacological Intervention in Depression After Traumatic Brain Injury
Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System)
Status: Enrolling
Updated: 3/16/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation
Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)
Status: Enrolling
Updated:  3/16/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation
Acute Cognitive and Neurobehavioral Intervention: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)
Status: Enrolling
Updated: 3/16/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Fairhope, AL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Fairhope, AL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Mobile, AL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Montgomery, AL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Montgomery, AL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Little Rock, AR
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Arcadia, CA
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Arcadia, CA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Glendale, CA
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Glendale, CA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Laguna Hills, CA
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Pasadena, CA
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Boca Raton, FL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Melbourne, FL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Melbourne, FL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Miami, FL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Chicago, IL
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Kansas City, KA
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Kansas City, KA
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Baltimore, MD
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Royal Oak, MI
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
Mineola, NY
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated:  3/21/2017
GSK Investigational Site
mi
from
New Hyde Park, NY
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status: Enrolling
Updated: 3/21/2017
GSK Investigational Site
mi
from
New Hyde Park, NY
Click here to add this to my saved trials